
Cognitive impairment is a core feature of schizophrenia and remains insufficiently addressed by current treatments. Increasing evidence implicates the cholinergic system, particularly the basal forebrain cholinergic nuclei (BFCN), in cognitive dysfunction. While structural alterations of the BFCN have been reported, alterations in their intrinsic functional connectivity (iFC) remain unclear. The present study examined the iFC of anterior and posterior BFCN subdivisions (aBFCN, pBFCN) in schizophrenia and tested associations with cognitive performance. Resting-state functional magnetic resonance imaging data from the COBRE dataset were analyzed, including 73 healthy controls (HC) and 51 patients with schizophrenia (SCZ). Seed-based connectivity analyses were performed for aBFCN and pBFCN. Group differences were assessed voxel-wise, and group-dependent associations with phonemic verbal fluency (FAS) and processing speed (BACS-SC) were tested using hierarchical regression controlling for age, sex, IQ, and smoking status; verbal learning and memory (HVLT) was examined as a specificity analysis. Exploratory molecular mapping used normative PET-derived neurotransmitter maps, supplemented by spatial-autocorrelation-preserving null models. Distinct connectivity patterns of aBFCN and pBFCN were observed, consistent with previous reports in HC. Compared with HC, SCZ showed reduced pBFCN connectivity with a cluster in the right inferior frontal gyrus (pars opercularis; BA44; p = 0.018, FWE-corrected), whereas no significant differences were observed for aBFCN. The Group × pBFCN–IFG connectivity interaction was significant for FAS (p = 0.014) but not BACS-SC (p = 0.762) or HVLT (p = 0.514). In SCZ, higher pBFCN–IFG connectivity was associated with better FAS performance. Descriptive molecular mapping showed above-average representation of M1 and α4β2 receptor maps as well as several non-cholinergic targets; however, no molecular target showed significant spatial correspondence after spatial-autocorrelation-aware testing and FDR correction. These findings provide evidence for selective pBFCN hypoconnectivity with the right inferior frontal gyrus in schizophrenia. Its association with verbal fluency suggests that disrupted pBFCN connectivity with the inferior frontal cortex may contribute to altered executive control processes involved in verbal fluency in schizophrenia. Together, these findings extend previous evidence of BFCN abnormalities in schizophrenia by demonstrating a systems-level functional alteration of pBFCN–cortical connectivity and its relationship with cognitive performance.
Childhood trauma, anhedonia, and educational attainment have been associated with psychosis, but their independent associations with drug-naïve first-episode schizophrenia spectrum disorders (FESSD) remain unclear. We examined the associations of childhood trauma, anhedonia, and sociodemographic factors with FESSD case status and symptom severity in an drug-naïve sample. In this cross-sectional case-control study, 274 participants, including 107 individuals with FESSD and 167 healthy controls, were assessed for childhood trauma and anhedonia. Multivariable logistic regression was used to identify factors independently associated with case status, and linear regression examined symptom severity within the FESSD group. Childhood trauma was independently associated with higher odds of FESSD (odds ratio [OR] = 5.38, 95% confidence interval [CI] 2.85–10.16, P < 0.001), as was greater anhedonia (OR = 1.78, 95% CI 1.29–2.46, P < 0.001), whereas higher educational attainment was inversely associated with case status (OR = 0.55, 95% CI 0.39–0.77, P < 0.001). These associations remained directionally consistent in sensitivity analyses restricted to patients with illness duration ≤12 months and patients with duration of untreated psychosis (DUP) ≤ 12 months. Sensitivity analyses using the Dimensional Anhedonia Rating Scale (DARS) yielded consistent findings, with higher hedonic capacity associated with lower odds of FESSD (OR = 0.44, 95% CI 0.31–0.63, P < 0.001). Childhood trauma also demonstrated a dose–response association with case status, and the overall findings remained robust across sensitivity analyses. In exploratory within-patient analyses, higher SHAPS scores were nominally associated with greater PANSS negative symptom severity (β = 0.22, 95% CI 0.03–0.41, unadjusted P = 0.027), but this association did not remain statistically significant after correction for multiple testing (FDR-adjusted P = 0.278). These findings identify childhood trauma as a retrospectively assessed developmental correlate and anhedonia as a contemporaneous clinical correlate of FESSD case status, while educational attainment shows an inverse association that may reflect both developmental and illness-related processes. However, these associations should not be interpreted as evidence of premorbid vulnerability or causality. Longitudinal studies are needed to establish their temporal relationships.
Neuroimaging has transformed the study of psychosis spectrum disorders (PSD), yielding major advances in our understanding of disease biology across molecular, circuit, and systems levels. Positron emission tomography established robust evidence for striatal dopamine dysfunction; magnetic resonance spectroscopy identified glutamatergic abnormalities, particularly early in illness; task-based functional MRI revealed impaired fronto-parietal recruitment during cognitive operations such as working memory; and resting-state fMRI uncovered widespread alterations in thalamo-cortical organization. Yet despite these achievements, the field has struggled to translate biological insight into precision therapeutics. A central limitation is the absence of reproducible brain–behavior associations, formalized here as neuro-phenotype geometry (NPG). NPG refers to the reproducible structure of associations between inter-individual variation in neural systems and clinically meaningful variation in symptoms, cognition, function, and illness trajectory. We argue that reproducible NPG is a central statistical object for imaging-enabled therapeutic development because both patient selection and endpoint optimization depend on it. Furthermore, translation also requires alignment with endpoints on a regulatory path, which in PSD remains narrow, centered largely on PANSS-based symptom measures and MATRICS-informed cognition. Robust NPG signatures should be linked to disease-modifying mechanisms through neurobiologically grounded computational models, situated within longitudinal designs that respect the dynamic nature of illness, and derived from multimodal datasets capable of capturing pathophysiology across scales. This agenda defines the scientific and translational priorities needed to unlock genuinely mechanism-based precision treatment in psychosis.
Schizophrenia has been associated with peripheral inflammatory and metabolic changes, but the relative value of routine blood-derived composite indices remains uncertain. We compared eight inflammatory–nutritional indices in 146 patients hospitalized with acute-phase schizophrenia and 146 age- and sex-matched healthy controls; 93 patients underwent repeat blood testing after clinical improvement during routine antipsychotic treatment. After FDR correction, NLR, MLR, PLR, SII, NPAR, and PAR were higher in SCZ, whereas PNI and AAPR were lower. MLR showed the strongest single-index case–control discrimination (AUC, 0.797). Screening all 84 two- and three-index models identified MLR + PNI + AAPR (apparent AUC, 0.854). Selection-aware bootstrap validation yielded an optimism-corrected AUC of 0.839, and the same panel was re-selected in 49.7% of resamples. A sensitivity model using the four underlying laboratory variables directly (monocyte count, lymphocyte count, albumin, and alkaline phosphatase) achieved a slightly higher apparent AUC of 0.867, indicating that the derived ratios offered no discrimination advantage over their components. During follow-up, SII, PAR, and NLR decreased, whereas PNI and AAPR did not change significantly. Exploratory medication analyses showed no FDR-significant difference in biomarker change between monotherapy and combination treatment, and the standardized final-dose ratio was not associated with biomarker change. Because all patients received routine treatment and there was no untreated comparison group, the longitudinal findings are interpreted as changes observed during follow-up rather than direct treatment effects. These indices may add low-cost information to routine blood tests but are not diagnostic tools.
Psychosis risk calculators are widely used to estimate the likelihood of conversion among individuals at clinical high risk (CHR) for psychosis; however, conversion represents only a minority of outcomes, and the broader clinical utility of these tools remains unclear. This study validated the performance of the North American Prodrome Longitudinal Study (NAPLS-2 RC) risk calculator in a fully remote, longitudinal CHR sample (n = 369; 23 converters) and examined whether its predictive utility extends beyond psychosis conversion to other clinically meaningful outcomes. Outcomes included conversion to psychosis, illness progression, remission, newly onset mood disorders, mood disorder relapse, and psychotropic medication initiation. The NAPLS-2 RC demonstrated fair discrimination when predicting conversion within two years (AUC = 0.66) within the fully remote study. The NAPLS-2 RC also showed fair discrimination for remission (AUC = 0.63) and antidepressant initiation (AUC = 0.63). In contrast, the calculator showed poor discrimination for illness progression (AUC = 0.51), mood disorder onset (AUC = 0.56), mood disorder relapse (AUC = 0.54), and antipsychotic initiation (AUC = 0.49). These findings suggest that the NAPLS-2 risk calculator demonstrates relative specificity for psychosis-related outcomes and may be useful as a screening tool to guide further evaluation.